Women with vaginitis symptoms were significantly more likely to receive appropriate treatment within 24 hours when tested with a multiplex molecular point-of-care test compared with standard diagnostic methods, according to results from the first randomized clinical trial evaluating this approach. The study, published in Sexually Transmitted Diseases, enrolled 276 women at a single site between July 2024 and February 2025.
The trial was led by investigators at Magee-Womens Research Institute and the University of Pittsburgh and supported by an investigator-initiated grant from Cepheid, the manufacturer of the test. That funding source should be considered when interpreting the results, though the study design was randomized and the outcomes were independently measured.
The test under evaluation was the Xpert Xpress MVP (multiplex vaginal panel), a CLIA-waived nucleic acid amplification test that detects bacterial vaginosis, vulvovaginal candidiasis, and Trichomonas vaginalis from a single self-collected vaginal sample. In the usual care arm, standard diagnostic methods included symptom-based assessment, pH testing, odor evaluation, and wet mount microscopy.
Nearly 90% received correct treatment within a day
Among women tested with Xpert Xpress MVP, 89.6% received appropriate treatment within 24 hours of their clinic visit, compared with 51.9% in the usual care arm — a statistically significant difference (P < 0.001). The advantage held for each individual infection type: bacterial vaginosis, candidiasis, and even cases where no pathogen was present.
Related: User reports platform error after account blocked
That last point turned out to be important. Among women confirmed to have no vaginal infection, 50% in the usual care arm received unnecessary antimicrobial treatment, compared with 27.1% in the Xpert Xpress MVP arm (P = 0.031). The study authors noted that overuse of antimicrobials contributes to resistance, disrupts the vaginal microbiome, and adds costs to patients and insurers.
The prevalence of infection in the study population was relatively high: bacterial vaginosis was found in 44.7% of women, candidiasis in 32%, and Trichomonas vaginalis in 5.1%. More than a third of women — 36.9% — had no detectable pathogens at all, which shows the risk of guessing wrong with symptom-based care.
It’s plausible that broader adoption of such point-of-care molecular testing could shift how vaginitis is managed in clinics, particularly those that see high volumes of women with recurring symptoms. But the real-world impact will depend on cost, reimbursement, and whether the test can be integrated into workflows without slowing down visits. The study shows promise in a controlled research setting; wider implementation would require additional data on routine use.
Providers liked the test, and they had good reason
Among healthcare providers whose patients were randomized to the Xpert Xpress MVP arm, 87% said they would like to incorporate this type of testing into routine clinical practice. Most reported positive perceptions of the test’s turnaround time and workflow. The test runs on a GeneXpert instrument already common in many clinics.
Related: Sore Eyes Identified as Common COVID-19 Symptom
Connie Savor, MD, Chief Medical Officer at Cepheid, said in a statement: “Women presenting with vaginal symptoms deserve accurate answers and timely, evidence-based care. This study demonstrates how molecular point-of-care tests… can help clinicians make more informed treatment decisions in a single visit, improving care while reducing unnecessary treatment.”
The usual care arm showed just how often standard methods fall short. The investigators reported that 25% of providers relied solely on symptoms to guide treatment decisions, and standard approaches correctly identified infections only about 50% to 63% of the time. That data came from the same study, which defined true positives using two FDA-cleared NAATs as the reference standard.
The trial enrolled women seeking care for vaginal symptoms including discharge, odor, itch, irritation, burning, or pain. Median participant age was 33 years, with a range of 17 to 76. Racial distribution was 50% Black, 41% White, and 9% other; 7% of participants were pregnant.
